PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.

Fiona  Thistlethwaite

Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst); Zelluna

Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)

Travel, Accommodations, Expenses - GlaxoSmithKline; Zelluna

Other Relationship - iMatch

Aung  Naing

Consulting or Advisory Role - CytomX Therapeutics; Novartis

Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; Kyocera; Lilly; MedImmune; Merck; NCI; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; TopAlliance BioSciences Inc

Travel, Accommodations, Expenses - ARMO BioSciences

Marta  Gil-Martin

Travel, Accommodations, Expenses - MSD Oncology

Patricia  LoRusso

Honoraria - Five Prime Therapeutics

Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME

Research Funding - Genentech (Inst)

Travel, Accommodations, Expenses - Genentech

Manreet  Randhawa

Honoraria - Bayer

Travel, Accommodations, Expenses - Bayer

Ferry  Eskens

Honoraria - SERVIER

Consulting or Advisory Role - Eisai; Ipsen; Merck Serono; Roche

Travel, Accommodations, Expenses - Ipsen; Pfizer

Rachel E.  Sanborn

Honoraria - Amgen; AstraZeneca

Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Celldex; Genentech/Roche; Peregrine Pharmaceuticals; Seagen; Takeda

Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck

Travel, Accommodations, Expenses - AstraZeneca; Five Prime Therapeutics; Janssen Oncology

Nataliya Volodymyrivna  Uboha

Consulting or Advisory Role - AstraZeneca; EMD Serono; Flatiron Health; Gerson Lehrman Group; Incyte; ipsen; LEK; Lilly; Lilly; M3; Taiho Pharmaceutical

Research Funding - EMD Serono (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)

Daniel C.  Cho

Consulting or Advisory Role - HUYA Bioscience International; Nektar; Pfizer; PureTech; Torque

Expert Testimony - Abbott/AbbVie; Genentech

Alexander I.  Spira

Stock and Other Ownership Interests  - Lilly

Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda

Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis

Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)

Igor  Bondarenko

No Relationships to Disclose

Elizabeth Ruth  Plummer

Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro

Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis

Research Funding - AstraZeneca/MedImmune (Inst)

Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology

Javier  Garcia-Corbacho

No Relationships to Disclose

Iván  Victoria

No Relationships to Disclose

Javier  Lavernia

Consulting or Advisory Role - Bristol-Myers Squibb; PharmaMar; Sanofi

Speakers' Bureau - Bristol-Myers Squibb; Merck; PharmaMar; Roche

Travel, Accommodations, Expenses - Merck; MSD; PharmaMar

Ignacio  Melero

Honoraria - Alligator Bioscience; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; Roche/Genentech; Tusk Therapeutics

Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bayer; Biocotech; Biocotech; Bristol-Myers Squibb; EMD Serono; F-star; Genmab; Lilly; MSD; Numab; Roche; Tusk Therapeutics; Tusk Therapeutics

Research Funding - Alligator Bioscience; Bristol-Myers Squibb; Pfizer; Roche/Genentech

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech

Elisabeth  De Vries

Consulting or Advisory Role - Daiichi Sankyo (Inst); NSABP Foundation (Inst); Sanofi (Inst)

Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); CytomX Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Nordic Nanovector (Inst); Radius Health (Inst); Regeneron (Inst); Roche (Inst); Servier (Inst); Synthon (Inst)

(OPTIONAL) Uncompensated Relationships - ESMO (Inst); ESMO (Inst); RECIST Committee (Inst)

William  Garner

Employment - CytomX Therapeutics; Gilead Sciences; Kite/Gilead (I); MyoKardia (I)

Stock and Other Ownership Interests  - CytomX Therapeutics; Gilead Sciences; Gilead Sciences (I); MyoKardia (I)

Hendrik-Tobias  Arkenau

Employment - Hospital Corporation of America

Honoraria - BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER

Johanna C.  Bendell

Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)

Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical